The impact of ferritin fluctuations on stable hemoglobin levels in hemodialysis patients

Clinical and Experimental Nephrology

Volumn 16, Issue 3, 2012, Pages 448-455

  Yahiro, Mana ^a   Kuragano, Takahiro ^a   Kida, Aritoshi ^a   Kitamura, Rie ^a   Furuta, Minoru ^a   Hasuike, Yukiko ^a   Otaki, Yoshinaga ^a   Nonoguchi, Hiroshi ^a   Nakanishi, Takeshi ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Erythropoiesis stimulating agents; Ferritin fluctuation; Hb fluctuation; Iron; Renal anemia

Indexed keywords

FERRITIN; HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN;

ADULT; ARTICLE; FEMALE; FERRITIN BLOOD LEVEL; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON STORAGE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PROSPECTIVE STUDY;

AGED; ANEMIA; FEMALE; FERRITINS; FERROUS COMPOUNDS; HEMATINICS; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 84863684822     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-011-0584-0     Document Type: Article

References (22)

1. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, CHOIR Investigators, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085-98.
2. Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, CREATE Investigators, et al. Normalizaiton of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071-84.
3. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissnoson AR, Okamoto DM, et al. The effect of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339: 584-90.
4. Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int. 2005;68:1337-43.
5. Ebben JP, Gilbertson DT, Foley RN, Collins AJ. Hemoglobin level variability: Association with comorbidity, intercurrent events, and hospitalization. Clin J Am Soc Nephrol. 2006;1(6): 1205-10.
6. Yang W, Israni RK, Brunelli SM, Joffe MM, Fishbane S, Feldman HI. Hemoglobin variability and mortality in ESRD. J Am Soc Nephrol. 2007;18(12):3164-70.
7. Francisco ALM, Stenvinkel P, Vaulont S. Inflammation and its impact on anaemia in chronic kidney disease: From hemoglobin variability to hyporesponsiveness. NDT Plus. 2009;Suppl 1:i18-26.
8. Kalantar-Zadeh K, Aronoff GR. Hemoglobin variability in anemia of chronic kidney disease. J Am Soc Nephrol. 2009;20: 479-87.
9. Rozen-Zvi B, Gafter-Gvili A, Paul M, Leibovici L, Shpilberg O, Gafter U. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: Systematic review and meta-Analysis. Am J Kidey Dis. 2008;52(5):897-906.
10. Kletzmayr J, Hörl WH. Iron overload and cardiovascular complications in dialysis patients. Nephrol Dial Transplant. 2002;17(Suppl 2):25-9.
11. Drüeke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin AP, Marchais SJ, et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end stage renal disease. Circulation. 2002;106:2212-7.
12. Nakanishi T, Kuragano T, Nanami M, Otaki Y, Nonoguchi H, Hasuike Y. Importance of ferritin for optimizing anemia therapy in chronic kidney disease. Am J Nephrol. 2010;32(5):439-46.
13. Lim PS, Wei YH, Yu YL, Kho B. Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transplant. 1999;14:2680-7.
14. Daugirdas JT, Greene T, Depner TA, Gotch FA, Star RA. Relationship between apparent (single-pool) and true (double-pool) urea distribution volume. Kidney Int. 1999;56(5):1928-33.
15. Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease. J Jpn Soc Dial Ther. 2008;41(10):661-716.
16. Canavese C, Bergamo D, Ciccone G, Longo F, Fop F, Thea A, et al. Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients. Kidney Int. 2004;65:1091-8.
17. Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU, European Best Practice Guidelines Working Group, et al. Revised European Best Practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004;19(suppl 2):ii1-47.
18. Provenzano R, Schiller B, Rao M, Coyne D, Brenner L, Pereira BJ. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol. 2009;4(2): 386-93.
19. Lenga I, Lok C, Marticorena R, Hunter J, Dacouris N, Goldstein M. Role of oral iron in the management of long-Term hemodialysis patients. Clin J Am Soc Nephrol. 2007;2(4):688-93.
20. Vanoaica L, Darshan D, Richman L, Schümann K, Kühn LC. Intestinal ferritin H is required for an accurate control of iron absorption. Cell Metab. 2010;12(3):273-82.
21. Kuragano T, Shimonaka Y, Kida A, Furuta M, Nanami M, Otaki Y, et al. Determinants of hepcidin in patients on maintenance hemodialysis: role of inflammation. Am J Nephrol. 2010;31(6): 534-40.
22. Chen JJ. Regulation of protein synthesis by the heme-regulated eIF2alpha kinase: relevance to anemias. Blood. 2007;109(7): 2693-9.